SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Bataneant M)
 

Sökning: WFRF:(Bataneant M) > Care of patients wi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007283naa a2201345 4500
001oai:prod.swepub.kib.ki.se:151516464
003SwePub
008240701s2022 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1515164642 URI
024a https://doi.org/10.3389/fimmu.2022.10323582 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Abolhassani, Hu Karolinska Institutet4 aut
2451 0a Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021
264 c 2022-12-16
264 1b Frontiers Media SA,c 2022
520 a The J Project (JP) physician education and clinical research collaboration program was started in 2004 and includes by now 32 countries mostly in Eastern and Central Europe (ECE). Until the end of 2021, 344 inborn errors of immunity (IEI)-focused meetings were organized by the JP to raise awareness and facilitate the diagnosis and treatment of patients with IEI.ResultsIn this study, meeting profiles and major diagnostic and treatment parameters were studied. JP center leaders reported patients’ data from 30 countries representing a total population of 506 567 565. Two countries reported patients from JP centers (Konya, Turkey and Cairo University, Egypt). Diagnostic criteria were based on the 2020 update of classification by the IUIS Expert Committee on IEI. The number of JP meetings increased from 6 per year in 2004 and 2005 to 44 and 63 in 2020 and 2021, respectively. The cumulative number of meetings per country varied from 1 to 59 in various countries reflecting partly but not entirely the population of the respective countries. Altogether, 24,879 patients were reported giving an average prevalence of 4.9. Most of the patients had predominantly antibody deficiency (46,32%) followed by patients with combined immunodeficiencies (14.3%). The percentages of patients with bone marrow failure and phenocopies of IEI were less than 1 each. The number of patients was remarkably higher that those reported to the ESID Registry in 13 countries. Immunoglobulin (IgG) substitution was provided to 7,572 patients (5,693 intravenously) and 1,480 patients received hematopoietic stem cell therapy (HSCT). Searching for basic diagnostic parameters revealed the availability of immunochemistry and flow cytometry in 27 and 28 countries, respectively, and targeted gene sequencing and new generation sequencing was available in 21 and 18 countries. The number of IEI centers and experts in the field were 260 and 690, respectively. We found high correlation between the number of IEI centers and patients treated with intravenous IgG (IVIG) (correlation coefficient, cc, 0,916) and with those who were treated with HSCT (cc, 0,905). Similar correlation was found when the number of experts was compared with those treated with HSCT. However, the number of patients treated with subcutaneous Ig (SCIG) only slightly correlated with the number of experts (cc, 0,489) and no correlation was found between the number of centers and patients on SCIG (cc, 0,174).Conclusions1) this is the first study describing major diagnostic and treatment parameters of IEI care in countries of the JP; 2) the data suggest that the JP had tremendous impact on the development of IEI care in ECE; 3) our data help to define major future targets of JP activity in various countries; 4) we suggest that the number of IEI centers and IEI experts closely correlate to the most important treatment parameters; 5) we propose that specialist education among medical professionals plays pivotal role in increasing levels of diagnostics and adequate care of this vulnerable and still highly neglected patient population; 6) this study also provides the basis for further analysis of more specific aspects of IEI care including genetic diagnostics, disease specific prevalence, newborn screening and professional collaboration in JP countries.
700a Avcin, T4 aut
700a Bahceciler, N4 aut
700a Balashov, D4 aut
700a Bata, Z4 aut
700a Bataneant, M4 aut
700a Belevtsev, M4 aut
700a Bernatowska, E4 aut
700a Bidlo, J4 aut
700a Blazso, P4 aut
700a Boisson, B4 aut
700a Bolkov, M4 aut
700a Bondarenko, A4 aut
700a Boyarchuk, O4 aut
700a Bundschu, A4 aut
700a Casanova, JL4 aut
700a Chernishova, L4 aut
700a Ciznar, P4 aut
700a Csuerke, I4 aut
700a Erdos, M4 aut
700a Farkas, H4 aut
700a Fomina, DS4 aut
700a Galal, N4 aut
700a Goda, V4 aut
700a Guner, SN4 aut
700a Hauser, P4 aut
700a Ilyina, NI4 aut
700a Iremadze, T4 aut
700a Iritsyan, S4 aut
700a Ismaili-Jaha, V4 aut
700a Jesenak, M4 aut
700a Kelecic, J4 aut
700a Keles, S4 aut
700a Kindle, G4 aut
700a Kondratenko, IV4 aut
700a Kostyuchenko, L4 aut
700a Kovzel, E4 aut
700a Krivan, G4 aut
700a Kuli-Lito, G4 aut
700a Kumanovics, G4 aut
700a Kurjane, N4 aut
700a Latysheva, EA4 aut
700a Latysheva, TV4 aut
700a Lazar, I4 aut
700a Markelj, G4 aut
700a Markovic, M4 aut
700a Marodi, L4 aut
700a Mammadova, V4 aut
700a Medvecz, M4 aut
700a Miltner, N4 aut
700a Mironska, K4 aut
700a Modell, F4 aut
700a Modell, V4 aut
700a Mosdosi, B4 aut
700a Mukhina, AA4 aut
700a Murdjeva, M4 aut
700a Muzes, G4 aut
700a Nabieva, U4 aut
700a Nasrullayeva, G4 aut
700a Naumova, E4 aut
700a Nagy, K4 aut
700a Onozo, B4 aut
700a Orozbekova, B4 aut
700a Pac, M4 aut
700a Pagava, K4 aut
700a Pampura, AN4 aut
700a Pasic, S4 aut
700a Petrosyan, M4 aut
700a Petrovic, G4 aut
700a Pocek, L4 aut
700a Prodeus, AP4 aut
700a Reisli, I4 aut
700a Ress, K4 aut
700a Rezaei, N4 aut
700a Rodina, YA4 aut
700a Rumyantsev, AG4 aut
700a Sciuca, S4 aut
700a Sediva, A4 aut
700a Serban, M4 aut
700a Sharapova, S4 aut
700a Shcherbina, A4 aut
700a Sitkauskiene, B4 aut
700a Snimshchikova, I4 aut
700a Spahiu-Konjusha, S4 aut
700a Szolnoky, M4 aut
700a Szucs, G4 aut
700a Toplak, N4 aut
700a Toth, B4 aut
700a Tsyvkina, G4 aut
700a Tuzankina, I4 aut
700a Vlasova, E4 aut
700a Volokha, A4 aut
710a Karolinska Institutet4 org
773t Frontiers in immunologyd : Frontiers Media SAg 13, s. 1032358-q 13<1032358-x 1664-3224
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:151516464
8564 8u https://doi.org/10.3389/fimmu.2022.1032358

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy